FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Tananbaum James B.		 2. Issuer Name and Ticker or Trading Symbol

PARDES BIOSCIENCES, INC. [ PRDS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE, SUITE 250, PMB#052		 3. Date of Earliest Transaction (MM/DD/YYYY)

12/23/2021
(Street)

CARLSBAD, CA 92008
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

12/28/2021 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/23/2021  C(2)  4941250 A$0.00 4941250 I See Footnote (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock $0.00 12/23/2021  C (2)    4941250   (2) (2)Common Stock 4941250 $0.00 0 I See Footnote (2)
Explanation of Responses:
(2) In connection with the closing of Pardes Biosciences, Inc.'s (formerly known as FS Development Corp. II) business combination, shares of Class B Common Stock of FS Development Corp. II converted into common stock of the Issuer. These shares are held by FS Development Holdings II, LLC ("FSD Holdings II"). Each of Foresite Capital Management V, LLC ("FCMVLLC"), Foresite Capital Opportunity Management V, LLC ("FCOMVLLC"), Foresite Capital Fund V, L.P. ("Capital Fund V L.P."), Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V L.P.") and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

Remarks:
On December 28, 2021, the reporting person filed a Form 4 which contained a clerical error reporting that the reporting person beneficially owned 4,873,750 shares of Class B Common Stock of FS Development Corp. II prior to its business combination. In fact, as reported in this Form 4 Amendment, the reporting person beneficially owned 4,941,250 shares of Class B Common Stock. These shares are held by FSD Holdings II. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P., Opportunity Fund V L.P. and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Tananbaum James B.
C/O PARDES BIOSCIENCES, INC.
2173 SALK AVE, SUITE 250, PMB#052
CARLSBAD, CA 92008		XX

Foresite Capital Fund V, L.P.
900 LARKSPUR LANDING CIRCLE, SUITE 150
LARKSPUR, CA 94939
X

Foresite Capital Management V, LLC
900 LARKSPUR LANDING CIRCLE, SUITE 150
LARKSPUR, CA 94939
X

Foresite Capital Opportunity Fund V, L.P.
900 LARKSPUR LANDING CIRCLE, SUITE 150
LARKSPUR, CA 94939
X

Foresite Capital Opportunity Management V, LLC
900 LARKSPUR LANDING CIRCLE, SUITE 150
LARKSPUR, CA 94939
X
Signatures
/s/ Elizabeth Lacy, Attorney-in-Fact for James B. Tananbaum12/30/2021
**Signature of Reporting PersonDate

/s/ Dennis Ryan, on behalf of Foresite Capital Fund V, L.P.12/30/2021
**Signature of Reporting PersonDate

/s/ Dennis Ryan, on behalf of Foresite Capital Management V, LLC12/30/2021
**Signature of Reporting PersonDate

/s/ Dennis Ryan, on behalf of Foresite Capital Opportunity Fund V, L.P.12/30/2021
**Signature of Reporting PersonDate

/s/ Dennis Ryan, on behalf of Foresite Capital Opportunity Management V, LLC12/30/2021
**Signature of Reporting PersonDate

/s/ Dennis Ryan, as Attorney-in-Fact for Foresite Capital Fund V, L.P., Foresite Capital Management V, LLC, Foresite Capital Opportunity Fund V, L.P. and Foresite Capital Opportunity Management V, LLC12/30/2021
**Signature of Reporting PersonDate
FS Development Corporati... (NASDAQ:FSII)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas FS Development Corporati....
FS Development Corporati... (NASDAQ:FSII)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas FS Development Corporati....